NorthStrive Biosciences Announces Progress Updates to Phase III Timeline for AI-Driven Drug Discovery Program with Yuva Biosciences
Rhea-AI Summary
NorthStrive Biosciences (NASDAQ:ELAB) updated the Phase III timeline for its AI development program with strategic partner Yuva Biosciences. Phase III was initiated on December 17, 2025 and initially expected to last ~6–9 weeks. Upgraded sixth‑generation classifier models improve screening accuracy, and Yuva now expects Phase III results in Q2 2026. NorthStrive notes it does not control Yuva’s timeline and results remain subject to change.
Positive
- Improved sixth‑generation classifier models increase screening accuracy
- Refined candidate selection for more comprehensive in‑vitro validation
- Expected Q2 2026 results aim to support downstream development
Negative
- Phase III timeline extended beyond the original 6–9 week estimate
- NorthStrive lacks control over partner Yuva’s revised timeline
News Market Reaction – ELAB
On the day this news was published, ELAB declined 20.40%, reflecting a significant negative market reaction. Argus tracked a trough of -44.3% from its starting point during tracking. Our momentum scanner triggered 17 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $611K from the company's valuation, bringing the market cap to $2M at that time. Trading volume was exceptionally heavy at 7.2x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ELAB’s -40% move occurred as several biotech peers were also weak (e.g., SPRC -9.55%, REVB -9.66%, INDP -6.77%, UBX -29.14%) but with one notable gainer QLGN at +7.72%. Scanner data flags only 1 peer (BDRX -4.14%) in momentum, so the pattern appears more stock-specific than a unified sector rotation.
Previous Clinical trial,AI Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 17 | Phase III initiation | Positive | -29.7% | Started Phase III AI program to biologically validate prioritized small molecules. |
| Sep 04 | Phase II completion | Positive | -9.9% | Completed Phase II screening of 12 compound libraries using MitoNova AI. |
| Jun 17 | Phase II initiation | Positive | -1.0% | Initiated Phase II AI screening for obesity and cardiometabolic drug candidates. |
Similar AI/clinical program milestones for NorthStrive have repeatedly been followed by negative next-day price moves despite constructive operational updates.
Across prior 3 AI-driven development updates tagged "clinical trial,AI", ELAB has advanced its collaboration with Yuva Biosciences from Phase II initiation on Jun 17, 2025, to Phase II completion on Sep 4, 2025, and then to Phase III initiation on Dec 17, 2025. Each step described progress in obesity and cardiometabolic drug discovery using the MitoNova™ platform, yet 24-hour reactions were negative, with an average move of about -13.52%. Today’s Phase III timeline refinement continues this same program trajectory.
Historical Comparison
Past AI/clinical updates for this program saw 24h moves averaging -13.52%. The latest Phase III timing revision fits into this pattern of operational progress paired with weak price reactions.
Historically, NorthStrive’s AI program progressed from Phase II initiation to completion, then to Phase III initiation. The current news refines Phase III timelines and methodology but stays within the same obesity and muscle-preservation development path.
Market Pulse Summary
The stock dropped -20.4% in the session following this news. A negative reaction despite operational progress fits prior patterns for ELAB’s AI collaboration updates, which saw average 24-hour moves of about -13.52% after similar "clinical trial,AI" news. The refinement of Phase III timelines and use of improved classifier models offers a more robust study design, but past trading shows that financing structure, leverage from pre-paid equity facilities, and broader risk perceptions have often overshadowed technical program milestones.
Key Terms
in-vitro medical
mitochondrial medical
probiotic medical
glp-1 receptor agonists medical
ai platform technical
AI-generated analysis. Not financial advice.
NEWPORT BEACH, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- NorthStrive Biosciences Inc. (“NorthStrive Biosciences”), a subsidiary of PMGC Holdings Inc. (NASDAQ:ELAB) (“PMGC”), today announced a progress update to the anticipated completion timeline for Phase III of its AI Development Program with strategic partner Yuva Biosciences, Inc. (“Yuva Biosciences”).
On December 17, 2025, Northstrive Biosciences announced the initiation of Phase III, which was expected to last approximately 6 to 9 weeks.
Northstive Biosciences has been advised that Yuva Biosciences has an improved sixth-generation classifier models, representing a significant advancement in screening accuracy and sensitivity which will be applied to the Phase III study. These upgraded models enable a more refined selection of candidate compounds and a more comprehensive evaluation during the in-vitro validation stage.
In light of these improvements, NorthStrive Biosciences has been advised by Yuva Biosciences that the Phase III results are expected to be available in Q2 2026. Yuva Biosciences expects that extended timeline will result in more robust, reliable, and informative results to support downstream development efforts.
Northstrive Biosciences does not have control over the anticipated timeline provided by Yuva Biosciences, which remains subject to change and may occur before or after the currently expected date.
About Yuva Biosciences, Inc.
Yuva Biosciences, Inc. is a mitochondrial sciences AI company that uses advanced artificial intelligence to identify and develop therapeutic and natural candidates targeting aging-related pathways. Its proprietary AI platform, MitoNova™, integrates proprietary biological, chemical, and mitochondrial-function datasets to accelerate the discovery of compounds with the potential to improve cellular processes and overall tissue health. Multiple products incorporating compounds discovered by Yuva Biosciences are already on the market, including Revive+ by BosleyMD. Yuva Biosciences is headquartered in Birmingham, Alabama. For more information, please visit www.yuvabio.com.
About Northstrive Biosciences Inc.
Northstrive Biosciences Inc., a PMGC Holdings Inc. company, is a biopharmaceutical company focusing on the development and acquisition of cutting-edge aesthetic medicines. Northstrive’s lead asset, EL-22, leverages an engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. For more information, please visit www.northstrivebio.com.
About PMGC Holdings Inc.
PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. We are committed to exploring opportunities in multiple sectors to maximize growth and value. For more information, please visit https://www.pmgcholdings.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “believes,” “expects,” “plans,” “potential,” “would” and “future” or similar expressions such as “look forward” are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These and other risks are described more fully in PMGC’s filings with the United States Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 28, 2025, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
IR Contact:
IR@pmgcholdings.com
FAQ
When does NorthStrive (ELAB) now expect Phase III results with Yuva Biosciences?
Why was the Phase III timeline for ELAB extended beyond the initial 6–9 weeks?
Does NorthStrive control the revised Phase III timetable announced for ELAB?
How will Yuva’s sixth‑generation classifiers affect ELAB’s Phase III outcomes?
What should investors in ELAB watch for after this Phase III timeline update?
